New patients treated for PNE with desmopressin should only be prescribed an oral formulation.
PNE新患者仅限用去氨加压素的口服剂型。
Objective To study the adverse drug reaction (ADR) of desmopressin (DDAVP) in clinical application, improving clinical medication.
目的了解和分析去氨加压素在临床应用中不良反应，促进临床合理用药。
Prebiopsy desmopressin administration decreases the risk of bleeding and hematoma size in patients undergoing percutaneous kidney biopsy without a cost increase.
在经皮肾穿刺患者中，穿刺前给予去氨加压素减少出血风险、减少血肿大小，而不增加住院费用。
应用推荐